Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis – report of two filgotinib-treated cases and literature review
DOI:
https://doi.org/10.2340/1651-226X.2025.44298Keywords:
Janus kinase inhibitors, immune checkpoint inhibitors, enterocolitis, colitis, melanoma, case reportAbstract
Background and purpose: Treatment of cancer with immune checkpoint inhibitors (ICIs) entails a risk of immune-related adverse events (irAEs). Data on the treatment of immune-related enterocolitis (irEC) in patients with inadequate symptom control after treatment with standard therapy including corticosteroids, infliximab, and vedolizumab are scarce. Based on limited data, recommendations include treatment with the pan-Janus kinase (JAK) inhibitor tofacitinib. Filgotinib is a more recently developed JAK inhibitor with preferential inhibition of JAK1, which might imply a more favorable safety profile. Filgotinib is approved for the treatment of ulcerative colitis and might thus be an option in refractory irEC.
Patients and methods: We present two cases of metastatic melanoma treated with ICIs who developed corticosteroid and infliximab-refractory irEC. Given non-conventional pharmaceutical management, literature review was performed regarding mechanisms of action and safety profiles of JAK inhibitors.
Results: Both patients were treated with filgotinib, which resulted in rapid remission of symptoms in both cases. One of the patients was treated with off-label high-dose filgotinib, which has not been described previously. The rationale and safety regarding the use of JAK1 inhibitors in irAEs are discussed, including the seemingly diverging existing data on potential effects of JAK inhibition on ICI-induced anti-tumoral immune-responses. In addition, the rationale for the high-dose treatment is scrutinized.
Interpretation: This report suggests that filgotinib may be considered for treating irEC refractory to standard therapy.
Downloads
References
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073–126.
https://doi.org/10.1200/JCO.21.01440 DOI: https://doi.org/10.1200/JCO.21.01440
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217–38.
https://doi.org/10.1016/j.annonc.2022.10.001 DOI: https://doi.org/10.1016/j.annonc.2022.10.001
Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435.
https://doi.org/10.1136/jitc-2021-002435 DOI: https://doi.org/10.1136/jitc-2021-002435
Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18:102390.
https://doi.org/10.1016/j.autrev.2019.102390 DOI: https://doi.org/10.1016/j.autrev.2019.102390
Honap S, Agorogianni A, Colwill MJ, Mehta SK, Donovan F, Pollok R, et al. JAK inhibitors for inflammatory bowel disease: recent advances. Frontline Gastroenterol. 2024;15:59–69.
https://doi.org/10.1136/flgastro-2023-102400 DOI: https://doi.org/10.1136/flgastro-2023-102400
Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17:139–47.
https://doi.org/10.1016/j.cgh.2018.07.009 DOI: https://doi.org/10.1016/j.cgh.2018.07.009
Danese S, Ferrante M, Feagan BG, Peyrin-Biroulet L, Hibi T, Sandborn WJ, et al. Rapid and sustained symptom relief in patients with ulcerative colitis treated with filgotinib: data from the phase 2b/3 SELECTION trial. Am J Gastroenterol. 2023;118:138–47.
https://doi.org/10.14309/ajg.0000000000001979 DOI: https://doi.org/10.14309/ajg.0000000000001979
Palasik BN, Wang H. Tofacitinib, the first oral Janus kinase inhibitor approved for adult ulcerative colitis. J Pharm Pract. 2021;34:913–21.
https://doi.org/10.1177/0897190020953019 DOI: https://doi.org/10.1177/0897190020953019
Sasson SC, Slevin SM, Cheung VTF, Nassiri I, Olsson-Brown A, Fryer E, et al. Interferon-gamma-producing CD8(+) tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis. Gastroenterology. 2021;161:1229–1244.e1229.
https://doi.org/10.1053/j.gastro.2021.06.025 DOI: https://doi.org/10.1053/j.gastro.2021.06.025
Esfahani K, Hudson M, Batist G. Tofacitinib for refractory immune-related colitis from PD-1 therapy. N Engl J Med. 2020;382:2374–75.
https://doi.org/10.1056/NEJMc2002527 DOI: https://doi.org/10.1056/NEJMc2002527
Bishu S, Melia J, Sharfman W, Lao CD, Fecher LA, Higgins PDR. Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis. Gastroenterology. 2021;160:932–34.e933.
https://doi.org/10.1053/j.gastro.2020.10.029 DOI: https://doi.org/10.1053/j.gastro.2020.10.029
Sweep MWD, Tjan MJH, Gorris MAJ, Bol KF, Westdorp H. Case report: a severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib. Front Immunol. 2023;14:1212432.
https://doi.org/10.3389/fimmu.2023.1212432 DOI: https://doi.org/10.3389/fimmu.2023.1212432
Sleiman J, Brand RM, Pai R, Brand RE, Rhee J, Schwartz M, et al. Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways. Clin J Gastroenterol. 2023;16:680–4.
https://doi.org/10.1007/s12328-023-01826-6 DOI: https://doi.org/10.1007/s12328-023-01826-6
Holmstroem RB, Dahl EK, Helms M, Nielsen HV, Andersen JB, Bjerrum JT, et al. Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report. BMJ Open Gastroenterol. 2022;9:e000989.
https://doi.org/10.1136/bmjgast-2022-000989 DOI: https://doi.org/10.1136/bmjgast-2022-000989
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316–26.
https://doi.org/10.1056/NEJMoa2109927 DOI: https://doi.org/10.1056/NEJMoa2109927
European Medicines Agency. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. European Medicines Agency; 2022. Available from: https://www.ema.europa.eu/en/news/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic.
U.S. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death.
Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158:1554–73.e1512.
https://doi.org/10.1053/j.gastro.2020.01.001 DOI: https://doi.org/10.1053/j.gastro.2020.01.001
Mattay SS, Zamani M, Saturno D, Loftus EV, Jr., Ciorba MA, Yarur A, et al. Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis. Clin Gastroenterol Hepatol. 2024;22:961–70.e912.
https://doi.org/10.1016/j.cgh.2023.09.033 DOI: https://doi.org/10.1016/j.cgh.2023.09.033
Ingrassia JP, Maqsood MH, Gelfand JM, Weber BN, Bangalore S, Lo Sicco KI, et al. Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis. JAMA Dermatol. 2024;160:28–36.
https://doi.org/10.1001/jamadermatol.2023.4090 DOI: https://doi.org/10.1001/jamadermatol.2023.4090
Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023;82:1059–67.
https://doi.org/10.1136/ard-2023-224049 DOI: https://doi.org/10.1136/ard-2023-224049
Danese S, Argollo M, Le Berre C, Peyrin-Biroulet L. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019;68:1893–9.
https://doi.org/10.1136/gutjnl-2019-318448 DOI: https://doi.org/10.1136/gutjnl-2019-318448
Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58:953–62.
https://doi.org/10.1093/rheumatology/key339 DOI: https://doi.org/10.1093/rheumatology/key339
Schreiber S, Rogler G, Watanabe M, Vermeire S, Maaser C, Danese S, et al. Integrated safety analysis of filgotinib for ulcerative colitis: results from SELECTION and SELECTIONLTE. Aliment Pharmacol Ther. 2023;58:874–87.
https://doi.org/10.1111/apt.17674 DOI: https://doi.org/10.1111/apt.17674
Feagan BG, Danese S, Loftus EV, Jr., Vermeire S, Schreiber S, Ritter T, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372–84.
https://doi.org/10.1016/S0140-6736(21)00666-8 DOI: https://doi.org/10.1016/S0140-6736(21)00666-8
Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer. 2018;6:142.
https://doi.org/10.1186/s40425-018-0461-4 DOI: https://doi.org/10.1186/s40425-018-0461-4
Berinstein JA, Sheehan JL, Dias M, Berinstein EM, Steiner CA, Johnson LA, et al. Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study. Clin Gastroenterol Hepatol. 2021;19:2112–20.e2111.
https://doi.org/10.1016/j.cgh.2021.05.038 DOI: https://doi.org/10.1016/j.cgh.2021.05.038
Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–36.
https://doi.org/10.1056/NEJMoa1606910 DOI: https://doi.org/10.1056/NEJMoa1606910
Berinstein JA, Karl T, Patel A, Dolinger M, Barrett TA, Ahmed W, et al. Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience. Am J Gastroenterol. 2024;119(4):1421–5.
https://doi.org/10.14309/ajg.0000000000002674 DOI: https://doi.org/10.14309/ajg.0000000000002674
Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80:865–75.
https://doi.org/10.1136/annrheumdis-2020-219012 DOI: https://doi.org/10.1136/annrheumdis-2020-219012
Irving PM, Leung Y, Dubinsky MC. Review article: guide to tofacitinib dosing in patients with ulcerative colitis. Aliment Pharmacol Ther. 2022;56:1131–45.
https://doi.org/10.1111/apt.17185 DOI: https://doi.org/10.1111/apt.17185
Irani M, Fan C, Glassner K, Abraham BP. Clinical evaluation of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis (UC): patient selection and reported outcomes. Clin Exp Gastroenterol. 2023;16:21–28.
https://doi.org/10.2147/CEG.S367086 DOI: https://doi.org/10.2147/CEG.S367086
Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54:859–74.
https://doi.org/10.1007/s40262-015-0240-z DOI: https://doi.org/10.1007/s40262-015-0240-z
Westhovens R, Taylor PC, Alten R, Pavlova D, Enríquez-Sosa F, Mazur M, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017;76:998–1008.
https://doi.org/10.1136/annrheumdis-2016-210104 DOI: https://doi.org/10.1136/annrheumdis-2016-210104
Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76:1009–19.
https://doi.org/10.1136/annrheumdis-2016-210105 DOI: https://doi.org/10.1136/annrheumdis-2016-210105
Taylor PC, Choy E, Baraliakos X, Szekanecz Z, Xavier RM, Isaacs JD, et al. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases. Rheumatology (Oxford). 2024;63:298–308.
https://doi.org/10.1093/rheumatology/kead448 DOI: https://doi.org/10.1093/rheumatology/kead448
Le TN, Westerberg BD, Lea J. Vestibular neuritis: recent advances in etiology, diagnostic evaluation, and treatment. Adv Otorhinolaryngol. 2019;82:87–92.
https://doi.org/10.1159/000490275 DOI: https://doi.org/10.1159/000490275
Huss V, Bower H, Hellgren K, Frisell T, Askling J. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Ann Rheum Dis. 2023;82:911–9.
https://doi.org/10.1136/ard-2022-223636 DOI: https://doi.org/10.1136/ard-2022-223636
Lopez-Bergami P, Fitchman B, Ronai Z. Understanding signaling cascades in melanoma. Photochem Photobiol. 2008;84:289–306.
https://doi.org/10.1111/j.1751-1097.2007.00254.x DOI: https://doi.org/10.1111/j.1751-1097.2007.00254.x
Ni L, Lu J. Interferon gamma in cancer immunotherapy. Cancer Med. 2018;7:4509–16.
https://doi.org/10.1002/cam4.1700 DOI: https://doi.org/10.1002/cam4.1700
Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819–29.
https://doi.org/10.1056/NEJMoa1604958 DOI: https://doi.org/10.1056/NEJMoa1604958
Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017;7:188–201.
https://doi.org/10.1158/2159-8290.CD-16-1223 DOI: https://doi.org/10.1158/2159-8290.CD-16-1223
Greenfield G, McMullin MF, Mills K. Molecular pathogenesis of the myeloproliferative neoplasms. J Hematol Oncol. 2021;14:103.
https://doi.org/10.1186/s13045-021-01116-z DOI: https://doi.org/10.1186/s13045-021-01116-z
Nicholas C, Lesinski G. The Jak-STAT signal transduction pathway in melanoma. In: Breakthroughs in Melanoma Research, 2011, IntechOpen London, UK. DOI: https://doi.org/10.5772/18876
Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167:1540–54.e1512.
https://doi.org/10.1016/j.cell.2016.11.022 DOI: https://doi.org/10.1016/j.cell.2016.11.022
Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19:1189–201.
https://doi.org/10.1016/j.celrep.2017.04.031 DOI: https://doi.org/10.1016/j.celrep.2017.04.031
Chen W, Teo JMN, Yau SW, Wong MY, Lok CN, Che CM, et al. Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8(+) T cell exhaustion and curtails anti-PD-1 efficacy. Cell Rep. 2022;41:111647.
https://doi.org/10.1016/j.celrep.2022.111647 DOI: https://doi.org/10.1016/j.celrep.2022.111647
Shen H, Huang F, Zhang X, Ojo OA, Li Y, Trummell HQ, et al. Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling. Nat Commun. 2022;13:5013.
https://doi.org/10.1038/s41467-022-32754-7 DOI: https://doi.org/10.1038/s41467-022-32754-7
Zak J, Pratumchai I, Marro BS, Marquardt KL, Zavareh RB, Lairson LL et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science. 2024;384:eade8520.
https://doi.org/10.1126/science.ade8520 DOI: https://doi.org/10.1126/science.ade8520
Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science. 2024;384:eadf1329.
https://doi.org/10.1126/science.adf1329 DOI: https://doi.org/10.1126/science.adf1329
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Henrik Ekedahl, Gudbjörg Sigurjonsdottir, Viktoria Bergqvist, Björn Båtshake, Ana Carneiro, Jan Marsal
This work is licensed under a Creative Commons Attribution 4.0 International License.
